Page 2 - Caicun Zhou News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Frontline Serplulimab Plus Chemo Provides Consistent Survival Benefit in Squamous NSCLC

The addition of serplulimab to carboplatin and nab-paclitaxel significantly prolonged survival vs chemotherapy alone when used in the first-line treatment of patients with previously untreated locally advanced or metastatic squamous non–small cell lung cancer.

Caicun zhouChina national medical products administrationLung cancerShanghai pulmonary hospitalNational medical products administrationAstrum 004 trial2023 iaslc world conference on lung cancerSerplulimab plus carboplatin and nab paclitaxel

Selpercatinib delivers superior outcomes, may reduce the burden of NSCLC

Selpercatinib delivers superior outcomes, may reduce the burden of NSCLC
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

Bymatthew shinkleCaicun zhouLois mulliganMindy valcarcelEli lilly coQueen universityNew england journalTongji university schoolShanghai pulmonary hospitalEli lilly

AnHeart Therapeutics and Innovent Announce China s NMPA Has Accepted a New Drug Application for Taletrectinib (ROS1 Inhibitor)

AnHeart Therapeutics and Innovent Announce China s NMPA Has Accepted a New Drug Application for Taletrectinib (ROS1 Inhibitor)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesRhui zhouHong kongNew yorkBing yanCaicun zhouAdimab incyteCharlotte arnoldEli lillyIncyte corporationChina national medical products administrationDrug administrationInnovent biologics incEuropean lung cancer congressEuropean society of medical oncology congressMd anderson cancer center

Innovent and AnHeart Therapeutics Announce the National Medical Products Administration of China Has Accepted the New Drug Application for Taletrectinib (ROS1 Inhibitor)

/PRNewswire/ Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes.

New yorkUnited statesRhui zhouHong kongCaicun zhouEli lillyInnovent biologicsBing yanAdimab incyteIncyte corporationNational medical products administrationDrug administrationEuropean society of medical oncology congressMd anderson cancer centerEuropean lung cancer congressChina national medical products administration

Taletrectinib Under NMPA Review in China for Advanced or Metastatic ROS1+ NSCLC

The Center for Drug Evaluation of China’s National Medical Products Administration has accepted the new drug application seeking the approval of the next-generation ROS1 TKI taletrectinib for the treatment of patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer with prior exposure to a ROS1 TKI.

Rhui zhouBing yanCaicun zhouJ thor oncChina national medical products administrationDrug evaluationNational medical products administrationShanghai pulmonary hospitalHeart therapeuticsRos1 nsclcRos1 tki